We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

57 hedge funds and large institutions have $163M invested in Alder Biopharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

71% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 14

16% more funds holding

Funds holding: 49 → 57 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

26% less capital invested

Capital invested by funds: $220M → $163M (-$56.5M)

Holders
57
Holders Change
+8
Holders Change %
+16.33%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
24
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$17.2M
2
PHS
PFM Health Sciences
California
+$4.47M
3
SFM
Sphera Funds Management
Israel
+$2.27M
4
PC
PointState Capital
New York
+$1.51M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$2.27M
2
FCM
Farallon Capital Management
California
-$2.01M
3
Morgan Stanley
Morgan Stanley
New York
-$1.18M
4
BG
BlackRock Group
United Kingdom
-$283K
5
BIT
BlackRock Institutional Trust
California
-$231K
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
26
Nicholas Investment Partners
California
$626K -$16.9K -1,115 -2%
BIM
27
Bogle Investment Management
Massachusetts
$523K +$624K +41,312 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$512K +$30K +1,988 +5%
BIM
29
BlackRock Investment Management
Delaware
$503K +$1.74K +115 +0.3%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$493K +$2.93K +194 +0.5%
SIM
31
Spark Investment Management
New York
$486K +$95.2K +6,300 +20%
ARTA
32
A.R.T. Advisors
New York
$451K +$538K +35,597 New
TCIM
33
TIAA CREF Investment Management
New York
$426K +$42K +2,780 +9%
Wells Fargo
34
Wells Fargo
California
$358K -$153K -10,098 -26%
PIM
35
Partner Investment Management
California
$300K -$64K -4,233 -15%
TC
36
TFS Capital
Pennsylvania
$285K +$340K +22,472 New
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$258K +$27.1K +1,794 +10%
Citadel Advisors
38
Citadel Advisors
Florida
$233K +$277K +18,310 New
CS
39
Credit Suisse
Switzerland
$220K +$262K +17,364 New
SO
40
STRS Ohio
Ohio
$199K +$237K +15,700 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$186K +$1.27K +84 +0.6%
PP
42
PDT Partners
New York
$164K +$195K +12,914 New
Charles Schwab
43
Charles Schwab
California
$149K – – –
TA
44
Teachers Advisors
New York
$145K – – –
Deutsche Bank
45
Deutsche Bank
Germany
$128K +$32.7K +2,164 +27%
NFA
46
Nationwide Fund Advisors
Ohio
$79K +$1.97K +130 +2%
AIG
47
American International Group
New York
$66.3K -$60 -4 -0.1%
AllianceBernstein
48
AllianceBernstein
Tennessee
$66K -$16.6K -1,100 -17%
Bank of America
49
Bank of America
North Carolina
$56K +$66.5K +4,400 New
BJ
50
BlackRock Japan
Japan
$50K +$7.1K +470 +14%
1
2
3

ALDR Hedge Fund Activity: Q3 2014 in Review

57 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2014, worth a combined $163M — down 26% from $220M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ALDR positions and 4 closed out — a net gain of 8 holders — while 24 added to existing stakes and 14 trimmed.

The largest buyer was Jennison Associates, adding an estimated $17.2M. The largest seller was Franklin Resources, cutting an estimated $2.27M.

  • 57 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2014, up from 49 in Q2 2014.
  • Funds reported $163M of Alder Biopharmaceuticals stock for Q3 2014, down 26% quarter-over-quarter.
  • 12 funds opened new Alder Biopharmaceuticals positions in Q3 2014 and 4 closed out, a net change of +8 holders.
  • The largest Alder Biopharmaceuticals buyer in Q3 2014 was Jennison Associates, an estimated $17.2M added.
  • The largest Alder Biopharmaceuticals seller in Q3 2014 was Franklin Resources, an estimated $2.27M sold.

Based on aggregated 13F filings for Q3 2014.